Rejuvenation Technologies develops nucleoside-modified TERT mRNA used to extend telomeres, based on the technology that telomere shortening affects cell function. The company has developed in-vivo based therapeutics and cell therapies for aging and treating fatal diseases. Founded in 2012 in Mountain View, United States, the company has raised $15.2M in seed funding from investors including Khosla Ventures, Y Combinator, and LifeSpan Vision Ventures. Rejuvenation Technologies is developing nucleoside-modified TERT mRNA. The nucleoside-modified TERT mRNA is used to extend the telomeres. It is based on the technology that telomere shortening affects cell function. Founded in 2012, headquartered in Mountain View, United States.
← All startups
Rejuvenation Technologies
SeedRejuvenation Technologies develops nucleoside-modified TERT mRNA used to extend telomeres, based on the technology that telomere shortening affects cell function. The company has developed in-vivo based therapeutics and cell therapies for aging and treating fatal diseases. Founded in 2012 in Mountain View, United States, the company has raised $15.2M in seed funding from investors including Khosla Ventures, Y…
About
Business model
Pulmonology > Drugs > Pulmonary Fibrosis > Telomere Based,
Gastroenterology > Drugs > Liver Diseases,
Genomics > Applied Genomics > Clinical Genomics > Therapeutics,
Y Combinator Batches > 2019 > Summer
Team background
College Wise > Stanford University
Institutional investors
Khosla VenturesShandaAsymmetry VenturesMerchant Adventure Investment AdvisorsLongevitytech.fundY CombinatorLifeSpan Vision VenturesHHSXylo CapitalGBSCatalytic Impact FoundationBlueLotusReinforced VenturesDeep Ventures99 Startups
Latest coverage
📰 Browse funding news — rounds, valuations, and market moves for founders.
Investor directory
🗂️ Browse all funds in our directory — active VCs and growth investors by stage and sector.
Similar startups
Raising like Rejuvenation Technologies?
Analyze your pitch deck before your next raise.
Analyze My Deck →